Table 1 Participant demographics
|  | Total sample (N = 32) | Pain interference (n = 20a) | Sleep disturbance (n = 12a) |
|---|---|---|---|
Age (years), mean (SD) | 53.9 (10.3) | 53.2 (11.4) | 55.0 (8.5) |
Age at diagnosis (years), mean (SD) | 42.6 (9.5) | 42.4 (10.5) | 42.9 (8.1) |
Time since diagnosis (years), mean (SD) | 10.7 (9.4) | 9.2 (7.4) | 13.3 (12.0) |
Number of swollen joints at screening, mean (SD) | 9.4 (4.4) | 8.5 (4.0) | 10.9 (4.8) |
Number of tender joints at screening, mean (SD) | 10.2 (6.2) | 8.8 (3.6) | 12.7 (8.8) |
Female, n (%) | 21 (66) | 13 (65) | 8 (67) |
Race/ethnicity, n (%) | |||
 White, non-Hispanic | 20 (63) | 14 (70) | 6 (50) |
 Black or African American | 10 (31) | 4 (20) | 6 (50) |
 Asian | 1 (3) | 1 (5) | 0 |
 Other | 1 (3) | 1 (5) | 0 |
Current RA medication, n (%) | |||
 Biologic only | 1 (3) | 1 (5) | 0 |
 csDMARD only | 13 (41) | 6 (30) | 7 (58) |
 Both biologic and csDMARD | 17 (53) | 12 (60) | 5 (42) |
 Neither biologic nor csDMARDb | 1 (3) | 1 (5) | 0 |
Self-reported RA severity, n (%) | |||
 Mild | 0 | 0 | 0 |
 Moderate | 22 (69) | 14 (70) | 8 (67) |
 Severe | 10 (31) | 6 (30) | 4 (33) |